Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof
AssigneeCarsgen Therapeutics Co., Ltd.
InventorsHuamao Wang, Bo Song, Xiumei Cai
Life of this patent
Estimating the term…
Abstract
Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.
Claims13
A chimeric antigen receptor expressed on a surface of an immune effector cell, wherein said chimeric antigen receptor comprises an extracellular binding region, a transmembrane region and an intracellular signal region, wherein the extracellular binding region comprises a protein which specifically recognizes CLD18A2, and wherein said chimeric antigen receptor comprises any one of SEQ ID NOs:
- 19-22.
A nucleic acid encoding a chimeric antigen receptor expressed on a surface of an immune effector cell, comprising an extracellular binding region, a transmembrane region and an intracellular signal region, wherein the extracellular binding region comprises a protein which specifically recognizes CLD18A2, wherein the nucleic acid comprises any one of SEQ ID NO:
- 15-18.
An expression vector, comprising a nucleic acid encoding a chimeric antigen receptor expressed on a surface of an immune effector cell, comprising an extracellular binding region, a transmembrane region and an intracellular signal region, wherein the extracellular binding region comprises a protein which specifically recognizes CLD18A2, wherein the nucleic acid comprises any one of SEQ ID NO:
- 15-18.
A virus, comprising an expression vector comprising a nucleic acid encoding a chimeric antigen receptor expressed on a surface of an immune effector cell, comprising an extracellular binding region, a transmembrane region and an intracellular signal region, wherein the extracellular binding region comprises a protein which specifically recognizes CLD18A2, wherein the nucleic acid comprises any one of SEQ ID NO:
- 15-18.
Dependencies are inferred from the claim text.